Impact of the HLA Immunopeptidome on Survival of Leukemia Patients After Unrelated Donor Transplantation.

Pietro CrivelloEsteban Arrieta-BolañosMeilun HeTao WangStephanie FingersonShahinaz M Gadalla Sophie Paczesny Steven G E Marsh Stephanie J Lee Stephen R Spellman Yung-Tsi Bolon Katharina Fleischhauer

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)

PBM-GVH mismatches inform mortality risks after single class I HLA-mismatched UD-HCT, suggesting that prospective consideration of directional PBM-matching status might improve outcome. These findings highlight immunopeptidome divergence between mismatched HLA as a driver of clinical tolerability in UD-HCT.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
acute myeloid leukemia
randomized controlled trial
prognostic factors
risk factors
cardiovascular events
clinical trial
type diabetes
patient reported outcomes
mesenchymal stem cells
climate change
double blind
patient reported